Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 11, 2000, Pages 2441-2447

  Jarvik, Gail Pairitz ^a,b,d   Rozek, Laura S ^a,b   Brophy, Victoria H ^a   Hatsukami, Thomas S ^c   Richter, Rebecca J ^a   Schellenberg, Gerard D ^b,c   Furlong, Clement E ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Carotid artery disease; Genotypes; Paraoxonase; Phenotypes; Vascular disease

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ARTICLE; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; VASCULAR DISEASE;

EID: 0033758531     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.11.2441     Document Type: Article

References (43)

1. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
2. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
3. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
4. Genetic polymorphism of paraoxonase and the risk of coronary heart disease
5. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease
6. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects
7. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes
8. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study
9. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
10. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
11. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease
12. Paraoxonase PON1 polymorphism leu-met54 is associated with carotid atherosclerosis: Results of the Austrian Stroke Prevention Study
13. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients
14. Paraoxonase polymorphism Met-Leu54 Is associated with modified serum concentrations of the enzyme
15. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese
16. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
17. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites
18. Protection of lowdensity lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
19. The human paraoxonase polymorphism and atherosclerosis
20. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein
21. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein
22. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
23. Genetic polymorphism and inter-ethnic variability of plasma paraoxonase activity
24. The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman, and sarin
25. The molecular basis of the human serum paraoxonase activity polymorphism
26. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
27. Determination of paraoxonase (pon1) status requires more than genotyping
28. A simple salting out procedure for extracting DNA from human nucleated cells
29. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol
30. Enzymatic methods for quantification of lipoprotein lipids
31. Precipitation methods for quantification of lipoproteins
32. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
33. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, III: Comparability of apolipoprotein A-I values by use of international reference material
34. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon
35. Human and rabbit paraoxonases: Purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification
36. Quantification of human serum paraoxonase by enzyme-linked immunoassay: Population differences in protein concentrations
37. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols
38. Multipie genetic determinants of variation of plasma lipoproteins in Alberta Hutterites
39. Paraoxonase genotypes, lipoprotein lipase activity, and high density lipoproteins
40. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype
41. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin dependent diabetes mellitus
42. Serum paraoxonase after myocardial infarction